Charach Lior, Spitzer Avishay, Zusmanovitch Lior, Charach Gideon
Division of Gastroenterology, Laniado Medical Center, Netanya 4244916, Israel.
Oncology Institute, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv 6423906, Israel.
Life (Basel). 2024 Oct 5;14(10):1266. doi: 10.3390/life14101266.
Heart failure affects 1-2% of the population in developed countries. Hemogram biomarkers are cheap, rapid, readily accessible and are known to have prognostic benefit in cardiovascular, infectious and oncologic diseases.
The aim of the current study is to evaluate lymphocyte-to-white-blood-cell ratio (LWR) as a prognostic predictor in patients with heart failure. Patients with heart failure were recruited between January 2000 and July 2001. Exclusion criteria included metastatic malignancy, exposure to chemotherapy, radiotherapy or medications known to affect complete blood count.
338 patients were enrolled, 33 were excluded. Mean age was 70.1 ± 10.8, 225 patients were male (73%) and 80 were female (27%). All patients were divided into three groups according to LWR. Group 1 < 0.2, group 2-0.2 < LWR < 0.35 and group 3 > 0.35. Patients with LWR ratio < 0.2 had the poorest survival while patients in the highest LWR (ratio > 0.35) had the best long-term survival.
Patients with congestive heart failure and LWR < 0.2 showed significant increased mortality. LWR was shown as independent prognostic predictor for HF patients compared to other main outcome parameters, including CRP, NYHA, EF and LDL.
在发达国家，心力衰竭影响着1%至2%的人口。血常规生物标志物价格低廉、检测快速、易于获取，且已知在心血管疾病、感染性疾病和肿瘤疾病中具有预后价值。
本研究的目的是评估淋巴细胞与白细胞比值（LWR）作为心力衰竭患者的预后预测指标。2000年1月至2001年7月招募了心力衰竭患者。排除标准包括转移性恶性肿瘤、接受化疗、放疗或已知会影响全血细胞计数的药物治疗。
共纳入338例患者，排除33例。平均年龄为70.1±10.8岁，男性225例（73%），女性80例（27%）。所有患者根据LWR分为三组。第1组LWR<0.2，第2组0.2<LWR<0.35，第3组LWR>0.35。LWR比值<0.2的患者生存率最差，而LWR最高（比值>0.35）的患者长期生存率最佳。
充血性心力衰竭且LWR<0.2的患者死亡率显著增加。与其他主要结局参数（包括CRP、纽约心脏协会心功能分级、射血分数和低密度脂蛋白）相比，LWR被证明是心力衰竭患者的独立预后预测指标。
